

PRECEPTORSHIP PROGRAMME

Prostate Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

SINGAPORE

15-16 NOVEMBER 2017

Co-Chairs Ravindran Kanesvaran, SG
 Rosa Nadal Rios, US

ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Singapore
15-16 November 2017

CO-CHAIRS: Ravindran Kanesvaran, Singapore
Rosa Nadal Rios, United States of America

SPEAKERS: Arun Azad, Australia
Melvin Lee Kiang Chua, Singapore
Jin Wei Kwek, Singapore
Lui Shiong Lee, Singapore
Lisa Pickering, United Kingdom
Puay Hoon Tan, Singapore

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 15 November 2017

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - objectives and scientific introduction	Ravindran Kanesvaran, SG Rosa Nadal Rios, US
09:15-10:30 75'	SESSION 1 Screening, diagnosis and staging	Chair: Puay Hoon Tan, SG
20'	PSA screening and diagnosis	Lui Shiong Lee, SG
20'	Diagnosis and impact of pathology on prognosis	Puay Hoon Tan, SG
20'	Latest in imaging and staging classification	Jin Wei Kwek, SG
15'	Discussion	Faculty
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 2 Localized prostate cancer	Chair: Lui Shiong Lee, SG
20'	Role of radiotherapy	Melvin Lee Kiang Chua, SG
20'	Role of surgery	Lui Shiong Lee, SG
20'	Active surveillance	Rosa Nadal Rios, US
2x15'	2 x Participants clinical case discussion	Faculty
12:30-13:30	Lunch	
13:30-15:15 105'	SESSION 3 Advanced prostate cancer	Chair: Ravindran Kanesvaran, SG
15'	Presentation with lymphadenopathy	Melvin Lee Kiang Chua, SG
20'	Value and role of PSA as a tumour marker of response / relapse	Arun Azad, AU
10'	Managing urinary obstruction	Lui Shiong Lee, SG
	<u>Debate:</u> This house believes that locally-advanced prostate cancer should be treated with radiotherapy and hormone deprivation	
10'	Arguments For	Melvin Lee Kiang Chua, SG
10'	Arguments Against	Lui Shiong Lee, SG
10'	Discussion	Faculty
2x15'	2 x Participants clinical case discussion	Faculty
15:15-15:45	Coffee break	
15:45-17:15 90'	SESSION 4 Initial systemic therapy	Chair: Lisa Pickering, UK
30'	Chemohormonal therapy in Hormone-Sensitive Prostate Cancer (HSPC)	Ravindran Kanesvaran, SG
30'	Androgen Deprivation Therapy (ADT) in HSPC: To add abiraterone or docetaxel?	Lisa Pickering, UK
2x15'	2 x Participants clinical case discussion	Faculty
20:00	Dinner	

Thursday, 16 November 2017

08:30-10:00 90'	SESSION 5 Current treatment in Castration Resistant Prostate Cancer (CRPC)	Chair: Rosa Nadal Rios, US
30'	2 nd line hormone therapies and chemotherapy	Lisa Pickering, UK
30'	Chemotherapy	Arun Azad, AU
2x15'	2 x Participants clinical case discussion	Faculty
10:00-10:30	Coffee break	
10:30-12:00 90'	SESSION 6 CRPC: Bone modulation and the future	Chair: Arun Azad, AU
20'	Bone targeting (bisphosphonates, RANK ligands and radioisotopes)	Lisa Pickering, UK
30'	New drug targets (including PSMA targeted agents)	Arun Azad, AU
10'	Discussion: Sequencing of treatments	Faculty
2x15'	2 x Participants clinical case discussion	Faculty
12:00-12:15 15'	Conclusion and farewell	Rosa Nadal Rios, US
12:15-13:15	Lunch	

Note: Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion